Angiogenesis Redux: An Overall Protective Role of VEGF/KDR Signaling in the Microvasculature in Pulmonary Arterial Hypertension

Overview

Journal Arterioscler Thromb Vasc Biol

Date 2023 Sep 7

PMID 37675636

Authors

Ying Zhong

Paul B Yu

Affiliations

Soon will be listed here.

References

Swietlik E, Greene D, Zhu N, Megy K, Cogliano M, Rajaram S . Bayesian Inference Associates Rare Variants with Specific Phenotypes in Pulmonary Arterial Hypertension. Circ Genom Precis Med. 2020; . PMC: 7892262. DOI: 10.1161/CIRCGEN.120.003155. View

Cool C, Stewart J, Werahera P, Miller G, Williams R, Voelkel N . Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol. 1999; 155(2):411-9. PMC: 1866857. DOI: 10.1016/S0002-9440(10)65137-1. View

Winter M, Sharma S, Altmann J, Seidl V, Panzenbock A, Alimohammadi A . Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension. Basic Res Cardiol. 2020; 115(6):58. PMC: 7471204. DOI: 10.1007/s00395-020-0811-5. View

Christou H, Yoshida A, Arthur V, Morita T, Kourembanas S . Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol. 1998; 18(6):768-76. DOI: 10.1165/ajrcmb.18.6.2980. View

Voelkel N, Hoeper M, Maloney J, Tuder R . Vascular endothelial growth factor in pulmonary hypertension. Ann N Y Acad Sci. 1996; 796:186-93. DOI: 10.1111/j.1749-6632.1996.tb32580.x. View

Hlavaty A, Roustit M, Montani D, Chaumais M, Guignabert C, Humbert M . Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis. Br J Clin Pharmacol. 2022; 88(12):5227-5237. PMC: 9795981. DOI: 10.1111/bcp.15436. View

Ferrara N, Hillan K, Gerber H, Novotny W . Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3(5):391-400. DOI: 10.1038/nrd1381. View

Benisty J, McLaughlin V, Landzberg M, Rich J, Newburger J, Rich S . Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest. 2004; 126(4):1255-61. DOI: 10.1378/chest.126.4.1255. View

Zhu N, Swietlik E, Welch C, Pauciulo M, Hagen J, Zhou X . Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Med. 2021; 13(1):80. PMC: 8112021. DOI: 10.1186/s13073-021-00891-1. View

10.

Dean A, Gregorc T, Docherty C, Harvey K, Nilsen M, Morrell N . Role of the Aryl Hydrocarbon Receptor in Sugen 5416-induced Experimental Pulmonary Hypertension. Am J Respir Cell Mol Biol. 2017; 58(3):320-330. PMC: 5854960. DOI: 10.1165/rcmb.2017-0260OC. View

11.

Akiyama T, Sadahiro T, Yamada Y, Fujita R, Abe Y, Nakano K . Flk1 Deficiency and Hypoxia Synergistically Promote Endothelial Dysfunction, Vascular Remodeling, and Pulmonary Hypertension. Arterioscler Thromb Vasc Biol. 2023; 43(9):1668-1683. DOI: 10.1161/ATVBAHA.123.319266. View

12.

Glodkowska-Mrowka E, Gorska E, Ciurzynski M, Stelmaszczyk-Emmel A, Bienias P, Irzyk K . Pro- and antiangiogenic markers in patients with pulmonary complications of systemic scleroderma. Respir Physiol Neurobiol. 2014; 209:69-75. DOI: 10.1016/j.resp.2014.10.018. View

13.

Jamison B, Michel R . Different distribution of plexiform lesions in primary and secondary pulmonary hypertension. Hum Pathol. 1995; 26(9):987-93. DOI: 10.1016/0046-8177(95)90088-8. View

14.

Voelkel N, Gomez-Arroyo J . The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox. Am J Respir Cell Mol Biol. 2014; 51(4):474-84. DOI: 10.1165/rcmb.2014-0045TR. View

15.

Tuder R, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y . Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol. 2001; 195(3):367-74. DOI: 10.1002/path.953. View

16.

Jonigk D, Golpon H, Bockmeyer C, Maegel L, Hoeper M, Gottlieb J . Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol. 2011; 179(1):167-79. PMC: 3123793. DOI: 10.1016/j.ajpath.2011.03.040. View

17.

Zhou W, Liu K, Zeng L, He J, Gao X, Gu X . Targeting VEGF-A/VEGFR2 Y949 Signaling-Mediated Vascular Permeability Alleviates Hypoxic Pulmonary Hypertension. Circulation. 2022; 146(24):1855-1881. DOI: 10.1161/CIRCULATIONAHA.122.061900. View

18.

Tuder R, Flook B, Voelkel N . Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest. 1995; 95(4):1798-807. PMC: 295709. DOI: 10.1172/JCI117858. View

19.

Archer S, Rich S . Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation. 2000; 102(22):2781-91. DOI: 10.1161/01.cir.102.22.2781. View

20.

Eyries M, Montani D, Girerd B, Favrolt N, Riou M, Faivre L . Familial pulmonary arterial hypertension by heterozygous loss of function. Eur Respir J. 2020; 55(4). DOI: 10.1183/13993003.02165-2019. View